EUCTR2012-004863-29-BE进行中（未招募）1 期
Direct thrombin inhibitors versus low molecular weight heparins as thromboprophylaxis in Staphylococcus aureus bacteraemia. A prospective randomized controlled academic single-centre feasibility study
niversity Hospitals Leuven (Gasthuisberg)0 个研究点开始时间: 2013年1月29日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Positive blood culture for staphylococcus aureus in an adult patient with symptoms or signs of infection.
- •Indication for thromboprophylaxis
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •Contraindication for thromboprophylaxis.
- •Clinically significant active bleeding or risk of excessive bleeding.
- •Heparin-induced thrombocytopenia.
- •Severe liver and kidney disease.
- •Pregnancy and lactation.
研究者
相似试验
已完成
不适用
Thrombolytic Therapy In Sub Massive Pulmonary Thromo EmboliPulmonary Thrombo Emboli.Pulmonary embolism with mention of acute cor pulmonaleIRCT2014042017343N1cardiovascular research center,Shahid Beheshti University Of Medical Sience50
尚未招募
Unknown
A Study of Combination Antithrombin and Thrombomodulin Therapy for Septic DIC -Systematic review and meta-analysisJPRN-UMIN000049820The Japanese Society on Thrombosis and Hamostasis
已完成
不适用
Appropriateness of Antithrombotic agents use in stroke patients with atrial fibrillation in KoreaKCT0000244Seoul National University Bundang Hospital3,000
已完成
不适用
Effects of antithrombotic drugs on thrombosis and bleeding risk in patients undergoing thoracic surgerythrombosisbleedingBlood - Other blood disordersBlood - Clotting disordersACTRN12619001417178Ayten Saracoglu100
已完成
不适用
ong term anticoagulation with low-molecular-weight heparin in a cohort of early neurological rehabilitation patients: does an effective inhibition of activity of factor Xa and factor IIa occur, as well as an increase of tPA and TFPI-levels?prophylactic LMWH-administration due to temporary or lingering patient's immobility due to their neurological/neurosurgical disease (cohorts 3+4)therapeutic LMWH-administration due to atrial fibrillation, thrombotic or thrombembolic events (cohorts 1+2).administration of oral anticoagulants due to atrial fibrillation, thrombotic or thrombembolic events (cohort 5, control cohort)I74I48.1Arterial embolism and thrombosisPersistent atrial fibrillationDRKS00000083pharmazentrum frankfurtInstitut für Klinische PharmakologieKlinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main77